SCHEMBL6456504

SCHEMBL6456504

N[C@H]1CC[C@@H](Nc2ccc3ccccc3n2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 1/20 0.49
DDB1 Q16531 1/20 0.48
CRBN Q96SW2 1/20 0.48
PDE10A Q9Y233 4/20 0.47
PIM1 P11309 1/20 0.47
PIM2 Q9P1W9 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
MCHR1 Q99705 1/20 0.45
MAPK8 P45983 2/20 0.44
CCNE1 P24864 1/20 0.41
CDK2 P24941 1/20 0.41
MAPK9 P45984 1/20 0.41
MAPK10 P53779 1/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MALT1 Q9UDY8 2/20 0.41
KDM1A O60341 1/20 0.40
MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5943499 1.00 NCF1 (0.49) NCF1DDB1CRBNPDE10APIM1
Hydrochloric Acid SCHEMBL6924108 0.98 NCF1 (0.47) NCF1DDB1CRBNPDE10APIM1
Hydrochloric Acid SCHEMBL6463442 0.98 NCF1 (0.47) NCF1DDB1CRBNPDE10APIM1
SCHEMBL31620776 0.92 NCF1 (0.57) NCF1DDB1CRBNPDE10ANPC1
SCHEMBL24092000 0.85 MCHR1 (0.57) NCF1DDB1CRBNPDE10ANPC1
SCHEMBL29911218 0.85 MCHR1 (0.57) NCF1DDB1CRBNPDE10ANPC1
SCHEMBL16666168 0.85 NPC1 (0.56) NCF1DDB1CRBNPDE10ANPC1
SCHEMBL7698523 0.84 NPC1 (0.49) NCF1DDB1CRBNPDE10APIM1
SCHEMBL9056686 0.83 NPC1 (0.59) NCF1DDB1CRBNPDE10ANPC1
SCHEMBL6462658 0.83 MCHR1 (0.46) NCF1DDB1CRBNPDE10APIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US claimed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO claimed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP claimed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 NCF1 3990/4885DDB1 1370/4885CRBN 4481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.